Diet Drug Acomplia / Zimulti Dealt Blow as FDA Panel Says Keep It Off U.S. Market

Diet pill rimonabant (Acomplia / Zimulti) was dealt a major setback on June 13th when an FDA advisory panel of outside experts unanimously recommended that the regulatory agency not approve the novel weight-loss drug for sale in...

Sanofi: No 'Causal Relationship' Proven Between Acomplia and Suicidality

Sanofi-Aventis on June 13th insisted that no "causal relationship" has been established between diet drug rimonabant (Acomplia / Zimulti) and "suicidality," but pledged to immediately begin asking all patients in ongoing clinical...

Undaunted, drugmakers aim at diabetes

Despite recent setbacks for Glaxo, Takeda drugs, companies large and small to discuss possible entries in $8 billion market.

Thousands of experts converge in Chicago next week to discuss potential new diabetes drugs - a growing...

FDA: 30 Percent of U.S. Patients on Diet Drugs Also Take Antidepressants

While Sanofi-Aventis says patients on antidepressants should not take diet-drug rimonabant (Acomplia / Zimulti), the FDA says data it obtained for 2004-2006 showed that 30 percent of the 580,000 patients prescribed diet pills...

Feds Reject French Weight-Loss Drug

FDA Panel Heard Testimony That Rimonabant Increases Risk Of Suicidal Thoughts